Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
- PMID: 32396847
- PMCID: PMC8360766
- DOI: 10.1016/j.immuni.2020.04.014
Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
Abstract
CD8+ T cell exhaustion is a major barrier to current anti-cancer immunotherapies. Despite this, the developmental biology of exhausted CD8+ T cells (Tex) remains poorly defined, restraining improvement of strategies aimed at "re-invigorating" Tex cells. Here, we defined a four-cell-stage developmental framework for Tex cells. Two TCF1+ progenitor subsets were identified, one tissue restricted and quiescent and one more blood accessible, that gradually lost TCF1 as it divided and converted to a third intermediate Tex subset. This intermediate subset re-engaged some effector biology and increased upon PD-L1 blockade but ultimately converted into a fourth, terminally exhausted subset. By using transcriptional and epigenetic analyses, we identified the control mechanisms underlying subset transitions and defined a key interplay between TCF1, T-bet, and Tox in the process. These data reveal a four-stage developmental hierarchy for Tex cells and define the molecular, transcriptional, and epigenetic mechanisms that could provide opportunities to improve cancer immunotherapy.
Keywords: CD8; PD-1 blockade; T cell exhaustion lineage; T-bet; TCF1; Tox; cancer immunotherapy; chronic infection; epigenetics; exhaustion.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Interests E.J.W. is a member of the Parker Institute for Cancer Immunotherapy which supported these studies. E.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck, Roche, Pieris, Elstar, and Surface Oncology. E.J.W. has a patent licensing agreement on the PD-1 pathway with Roche/Genentech. E.J.W. is a founder of Arsenal Biosciences.
Figures







Comment in
-
Charting the Roadmap of T Cell Exhaustion.Immunity. 2020 May 19;52(5):724-726. doi: 10.1016/j.immuni.2020.04.019. Immunity. 2020. PMID: 32433943
Similar articles
-
Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade.Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):14113-14118. doi: 10.1073/pnas.1903520116. Epub 2019 Jun 21. Proc Natl Acad Sci U S A. 2019. PMID: 31227606 Free PMC article.
-
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.Science. 2016 Dec 2;354(6316):1160-1165. doi: 10.1126/science.aaf2807. Epub 2016 Oct 27. Science. 2016. PMID: 27789795 Free PMC article.
-
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.Immunity. 2019 Jan 15;50(1):195-211.e10. doi: 10.1016/j.immuni.2018.12.021. Epub 2019 Jan 8. Immunity. 2019. PMID: 30635237
-
CD8+ T Cell Exhaustion in Cancer.Front Immunol. 2021 Jul 20;12:715234. doi: 10.3389/fimmu.2021.715234. eCollection 2021. Front Immunol. 2021. PMID: 34354714 Free PMC article. Review.
-
Transcriptional regulatory network for the establishment of CD8+ T cell exhaustion.Exp Mol Med. 2021 Feb;53(2):202-209. doi: 10.1038/s12276-021-00568-0. Epub 2021 Feb 24. Exp Mol Med. 2021. PMID: 33627794 Free PMC article. Review.
Cited by
-
Antigen-driven EGR2 expression is required for exhausted CD8+ T cell stability and maintenance.Nat Commun. 2021 May 13;12(1):2782. doi: 10.1038/s41467-021-23044-9. Nat Commun. 2021. PMID: 33986293 Free PMC article.
-
TBX21 Methylation as a Potential Regulator of Immune Suppression in CMS1 Subtype Colorectal Cancer.Cancers (Basel). 2022 Sep 22;14(19):4594. doi: 10.3390/cancers14194594. Cancers (Basel). 2022. PMID: 36230517 Free PMC article.
-
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment.Nat Rev Cancer. 2023 Mar;23(3):173-188. doi: 10.1038/s41568-022-00531-9. Epub 2022 Dec 1. Nat Rev Cancer. 2023. PMID: 36456755 Free PMC article. Review.
-
Regulation of CD8+ T cells by lipid metabolism in cancer progression.Cell Mol Immunol. 2024 Nov;21(11):1215-1230. doi: 10.1038/s41423-024-01224-z. Epub 2024 Oct 14. Cell Mol Immunol. 2024. PMID: 39402302 Free PMC article. Review.
-
Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma.Oncoimmunology. 2022 Jan 2;11(1):2010894. doi: 10.1080/2162402X.2021.2010894. eCollection 2022. Oncoimmunology. 2022. PMID: 36524206 Free PMC article.
References
-
- Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, Utzschneider DT, von Hoesslin M, Cullen JG, Fan Y, et al. (2019). TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265–269. - PubMed
-
- Beltra JC, Bourbonnais S, Bédard N, Charpentier T, Boulangé M, Michaud E, Boufaied I, Bruneau J, Shoukry NH, Lamarre A, and Decaluwe H (2016). IL2Rβ-dependent signals drive terminal exhaustion and suppress memory development during chronic viral infection. Proc. Natl. Acad. Sci. USA 113, E5444–E5453. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 CA210944/CA/NCI NIH HHS/United States
- U19 AI117950/AI/NIAID NIH HHS/United States
- F99 CA234842/CA/NCI NIH HHS/United States
- K08 CA230157/CA/NCI NIH HHS/United States
- U19 AI082630/AI/NIAID NIH HHS/United States
- P50 CA174523/CA/NCI NIH HHS/United States
- R01 AI105343/AI/NIAID NIH HHS/United States
- T32 CA009140/CA/NCI NIH HHS/United States
- P01 CA114046/CA/NCI NIH HHS/United States
- P30 CA016520/CA/NCI NIH HHS/United States
- K00 CA234842/CA/NCI NIH HHS/United States
- T32 CA009615/CA/NCI NIH HHS/United States
- P01 AI108545/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials